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Abstract
OBJECTIVE—We evaluated whether the addition of carotid intima media thickness and plaque
(CIMT-P), and, a single nucleotide polymorphism on chromosome 9p21 (9p21) together improve
coronary heart disease (CHD) risk prediction in the ARIC study.
METHODS—Ten year CHD risk was estimated using the ARIC coronary risk score (ACRS)
alone and in combination with CIMT-P and 9p21 individually and together in White participants
(n=9338). Area under the receiver operating characteristic curve (AUC), model calibration, net
reclassification index (NRI), integrated discrimination index (IDI) and number of individuals
reclassified were estimated.
RESULTS—The AUC of the ACRS, ACRS+9p21, ACRS+CIMT-P and ACRS+CIMT-P+9p21
models were 0.748, 0.751, 0.763 and 0.766 respectively. The percentage of individuals
reclassified, model calibration, NRI and IDI improved when CIMT-P and 9p21 were added to the
ACRS only model (see manuscript).
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CONCLUSION—Addition of 9p21 allele information to CIMT-P minimally improves CHD risk
prediction in whites in the ARIC study.
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Introduction
A single nucleotide polymorphism (SNP) in chromosome 9p21 (9p21) has been associated
with coronary heart disease (CHD) in whites1–3. Data from the Atherosclerosis Risk In
Communities (ARIC) study 4 have suggested that adding 9p21 to traditional risk factors
(TRF) and similarly adding information on carotid intima media thickness (CIMT) and
presence or absence of plaque to TRF5 improves CHD risk prediction improves CHD risk
prediction. Studies have however suggested that 9p21 is not associated with CIMT6.
We therefore evaluated whether CIMT/ plaque information together with 9p21 further
improves CHD risk prediction in the ARIC study.
Materials and Methods
The ARIC study is a population based study of cardiovascular disease incidence that
recruited 15,792 middle aged individuals aged between 45 and 64 years of age in 1987–89
in four communities in the United States. A complete description of the study design,
objectives and sampling strategy have been previously described7. After excluding non-
whites [(n= 4314), because 9p21 is associated with CHD only in whites], individuals with
prevalent CHD (n= 1050), those missing TRF covariate data (n= 356), missing CIMT
+plaque information (n=606) or missing 9p21 data (n=386) there were 9,338 whites
available for the current analysis.
For the TRF model we used the ARIC coronary risk score or ACRS 8. The variables that
constitute the ACRS are presented in table 1.
Details about genotyping and ultrasound measurements are provided in the supplement. We
used the mean of the mean IMT of the far wall of the carotid arteries [distal 1 cm of the
common carotid artery, the carotid artery bifurcation (1 cm proximal to the flow divider) and
the proximal 1cm of the internal carotid artery] and the presence/ absence of plaque for our
analysis. Missing CIMT values were imputed.
Incident Coronary Heart Disease Events
Incident CHD events included for our analysis included fatal CHD, definite or probable
myocardial infarction (MI), silent MI between examinations indicated by electrocardiograms
and coronary revascularization. Follow up for incident CHD was from baseline until
December 31st 2004. Methods for ascertainment of incident CHD events in ARIC have been
previously validated and published9.
Statistical Methods
Please refer to supplement for detailed statistical methods. Briefly, individuals were
classified into low, low-intermediate, intermediate-high and high risk (0–5%, 5–10%, 10–
20% and >20% predicted 10 year CHD risk respectively) groups using ACRS to form the
TRF model.
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Information about the 9p21 genotype and CIMT/plaque were added to the TRF model
individually and together resulting in the following models: i. TRF –only (ACRS based); ii.
TRF+9p21 iii. TRF+CIMT+plaque; and iv. TRF+9p21 +CIMT +plaque models. The
number of individuals reclassified to a higher or lower risk group by adding 9p21 and CIMT
+plaque alone or together to the TRF model was described.
To evaluate the model performance in risk prediction we performed tests to evaluate model
discrimination and calibration: We then described the area under the receiver operator
characteristic curve (AUC), net reclassification index (NRI), clinical NRI (i.e. NRI in the
intermediate risk groups [5–20% 10-year predicted CHD risk)], integrated discrimination
index (IDI) and % reclassified for 10-year risk using methods that accounted for
censoring1011. Using bootstraps we calculated the 95% confidence intervals when one
model was compared with another. Model calibration was tested using the Grønnesby-
Borgan goodness of fit test statistic12.
Experimental Results
Over a mean follow up of 14.7 years there were 1,231 incident CHD events (74 CHD
deaths, 612 myocardial infarctions, and 545 coronary revascularizations). The baseline
characteristics of the study cohort are described in supplemental tables1a and1b. The
baseline mean CIMT was 0.71 mm and the distribution of genotypes GG, AG, AA, of the
rs10757274 variant was 24%, 50% and 26% respectively; 9p21 was associated with a
hazards ratio of 1.21 (95% CI 1.12,1.31) after adjusting for ACRS+C-IMT+plaque
(Supplemental Table 2).
Addition of 9p21 or CIMT+plaque individually to the TRF model significantly improved the
AUC with the improvement being greater for the addition of CIMT+plaque; the largest
impovement was obtained when both CIMT/plaque and 9p21 were added to the TRF model
(Table 1).
Adding 9p21 to the TRF model reclassified 8.9% while adding CIMT+plaque reclassified
24.7% and adding both 9p21 information and CIMT+plaque reclassified 25.9% (Table 2,
Supplemental Table 3) of the individuals. No individualwas reclassified from the high to
low risk group or vice versa for any of the model comparisons.
When the NRI and clinical NRI were examined, the addition of 9p21 improved only the
clinical NRI while the addition of CIMT+plaque improved both the NRI and clinical NRI.
However, the addition of CIMT+plaque and 9p21 provided the largest increases in NRI and
clinical NRI (Table 2). The results of the integrated discrimination index (IDI) were similar
(Table 2).
When model fit was examined, both the model adding CIMT+plaque and the model adding
CIMT+plaque+9p21to TRF showed improved fit while the model adding 9p21 to TRF did
not improve model fit (Table 2).
Finally we evaluated the addition of CIMT+plaque to a model that included TRF+9p21 and
similarly added 9p21 to a model that included TRF+CIMT+plaque. Both of these
significantly improved the AUC (Table 1). When 9p21 was added to a TRF+C1IMT+plaque
model, 8.6% of the individuals were reclassified and the resulting NRI and clinical NRI
were 1.5% and 6.2% respectively. On the other hand, addition of CIMT+plaque to a base
model that included TRF and 9p21 resulted in larger improvements with 25.2% being
reclassified and a resulting NRI of 10.3% and clinical NRI of 29.8%.
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Traditional risk factors form the basis of any CHD risk prediction score used clinically8.
However, there is significant room for improvement in CHD risk prediction. Several
additional markers including biomarkers, imaging markers and genetic markers have been
and will continue to be evaluated for their ability to improve CHD risk prediction. Although
several efforts have examined the combination of multiple biomarkers13 or genotypes 14
none have combined these biomarkers/ genetic markers of higher risk with imaging markers.
We now report that a genetic marker (9p21 genotype) and an imaging marker (CIMT and
plaque presence) (that we have previously shown to individually improve CHD risk
prediction4, 5) in combination improved CHD risk prediction beyond that offered by each
marker alone. Although several studies have documented the association between the 9p21
variant and CHD,1, 2 no association between 9p21 and CIMT has been shown6. In the ARIC
study, 9p21 was associated with body mass index but with no other TRF.4 The utility of
9p21 in CHD risk prediction has been tested, but yielded mixed results. Two studies, one
that included only men2 and another that included only women,15 did not show significant
improvements in CHD risk prediction with the addition of 9p21. However, in the ARIC
study, which included men and women, and had a greater number of events than these other
studies, a modest, yet significant improvement was noted4.
CIMT and plaque are associated with both TRF and CHD, and, improve CHD risk
prediction when added to TRF5. We hypothesized that given the lack of association between
9p21 and CIMT, their ability to improve CHD risk prediction will be additive to each other
and indeed found this to be true. We used the ACRS as the TRF model given that ACRS is
the best CHD prediction model in ARIC. Use of Framingham risk score (i.e. the TRF model
recommended by ATP III) will likely have resulted in weaker TRF associations and greater
improvements in risk prediction by the novel risk factors as seen in our previous
analyses4, 5.
Although, our analysis suggests that adding both 9p21 and CIMT+plaque decreases the
number of individuals in the intermediate risk groups by ~10% and overall improves risk
prediction the clinical impact/ relevance is likely to be minimal as the addition of CIMT
+plaque accounted for most of the improvement. However, our analysis provides a proof of
concept that the addition of genetic markers to imaging markers may further improve the
ability of each marker to predict CHD risk. In the future as the field of genomics further
advances, additional genetic risk scores are likely to be described and when combined with
biomarker and imaging markers may yield better risk prediction tools.
Limitations
Our data cannot be generalized to all races. Specifically, our results pertain only to whites as
9p21 has been associated with CHD only in whites and not in African Americans
(Franceschini et al submitted). Our risk models used data from the baseline ARIC visit only.
Therapies and risk factors will likely have changed during the follow up time period.
However, this is true for any risk prediction model/effort.
Conclusion
We used one genetic marker (a SNP in 9p21) and one imaging marker (CIMT + assessment
of presence or absence of plaque), both of which have previously been shown to be
associated with CHD and improve CHD risk prediction, in combination and now show that
the combination of these two markers further marginally improves CHD risk prediction in
whites.
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• CIMT/ plaque and 9p21 SNP are known to be associated with CHD
• CIMT/ plaque and 9p21 SNP can improve CHD risk prediction
• We now show that combining CIMT/plaque, 9p21 further marginally improves
CHD risk prediction
• Improvements in CHD risk prediction conferred by adding CIMT/plaque were
greater than 9p21
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Area under the receiver operator characteristics curve and its differences when models adding information
related to the 9p21 allele, CIMT and plaque are compared to the ARIC coronary risk score alone in the
prediction of CHD incidence





ACRS + 9p21 0.751 0.003 0.001, 0.007
ACRS + CIMT + plaque 0.763 0.015 0.008, 0.021
ACRS + CIMT + plaque +9p21 0.766 0.018 0.011, 0.025
ACRS + 9p21 vs. ACRS + CIMT+plaque + 9p21 0.014 0.008, 0.021
ACRS + CIMT + plaque vs. ACRS + CIMT+plaque + 9p21 0.003 0.001, 0.007
ACRS: ARIC coronary risk score, includes age and its quadratic form (age2), gender, systolic blood pressure, antihypertensive medication use,
total cholesterol, high-density lipoprotein cholesterol (HDL-C), diabetes, and smoking status. Diabetes was defined as self reported diabetes or a
fasting serum glucose >126 mg/dL or use of blood sugar lower (anti-diabetes) medications or a non-fasting glucose >200 mg/dL.
CIMT : carotid intima media thickness
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Table 2
Statistical Parameters for Coronary Heart Disease Risk Prediction with the addition of 9p21 allele, CIMT and








% reclassified (#) 8.9 (n=828) 24.7% (n=2305) 25.9% (n=2416)
G-B goodness of fit test (p value) 15.75 (p=0.07) 17.6 (p=0.04) 14.48 (p=0.11) 15.27 (p=0.08)
NRI (%) (#) −0.5 8.3 9.8
Clinical NRI (%) (#) 4.1 25.01 28.6
IDI (#) 0.002 0.013 0.016
(#)
Comparison of various models to the ARS only model
(*)
Comparison of ARS+CIMT+plaque+9p21 allele to ARS+CIMT+plaque: % reclassified 8.6% (n=803), NRI 1.5%, clinical NRI 6.2%, IDI 0.002,
G-B: Grønnesby Borgan test of model calibration; NRI: Net reclassification index; clinical NRI: NRI in the intermediate (5–20% risk groups); IDI:
Integrated discrimination index
Atherosclerosis. Author manuscript; available in PMC 2013 May 01.
